Cardiosphere-Derived Cells and Extracellular Vesicles for Cardiac Rejuvenation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current rejuvenation strategies have not effectively addressed age-related heart dysfunction, and there is a need for methods and compositions to treat and modulate age-related disorders, including cardiovascular diseases associated with aging.
Innovation Solution
The use of cardiosphere-derived cells (CDCs) and their extracellular vesicles, such as exosomes and microvesicles, which can differentiate into heart cell types and exert paracrine effects to improve heart function and systemic health, reducing senescence and increasing telomerase activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional rejuvenation strategies (parabiosis, cellular reprogramming) are used, then some rejuvenation effects are achieved, but age-related heart dysfunction is not effectively addressed
Solution Approach 1:
The patent segments the rejuvenation approach by using extracellular vesicles (exosomes and microvesicles) as discrete carriers that can be isolated and administered separately from whole cells. This segmentation allows the therapeutic components to be delivered independently, enabling targeted treatment of heart dysfunction while achieving systemic rejuvenation effects.
Solution Approach 2:
The patent employs cardiosphere-derived cells as an intermediary system that produces extracellular vesicles containing rejuvenating factors. These vesicles act as mediators that transfer beneficial molecules (proteins, lipids, nucleic acids) from the cardiosphere-derived cells to target tissues, thereby addressing heart dysfunction indirectly through paracrine mechanisms rather than direct cell replacement.
2Reliability
If cardiosphere-derived cells are administered, then systemic rejuvenation and improved exercise tolerance are achieved, but the complexity of cell therapy increases
Solution Approach 1:
The patent extracts the therapeutic components (extracellular vesicles) from the source cells (cardiosphere-derived cells) and isolates them for administration. This extraction eliminates the need to administer entire living cells, thereby reducing the complexity associated with cell culture, expansion, and quality control while preserving the rejuvenating therapeutic effects in the isolated vesicles.
Solution Approach 2:
The patent uses cardiosphere-derived cells to produce copies of therapeutic molecules packaged within extracellular vesicles. These vesicles serve as copyable, stable therapeutic units that can be produced in bulk and stored, replacing the need for continuous cell culture and expansion while maintaining the systemic rejuvenation effects.
3Reliability
If extracellular vesicles from pediatric subjects are used, then enhanced rejuvenation effects are achieved, but the difficulty of obtaining suitable cell sources increases
Solution Approach 1:
The patent performs preliminary action by deriving and expanding cardiosphere-derived cells from pediatric heart tissue in advance, then using these pre-established cell lines to produce extracellular vesicles. This preliminary cell derivation and expansion allows the creation of a renewable source of pediatric-derived therapeutic vesicles, eliminating the need for repeated access to pediatric subjects while preserving the enhanced rejuvenation effects.
Data Source
AI summary
Described herein are compositions and methods related to use of cardiosphere-derived cells and their extracellular vesicles, such as exosomes and microvesicles, for achieving anti-aging and rejuvenation. This includes discoveries for effects on heart structure, function, gene expression, and systemic parameters. For animal studies, intra-cardiac injections of neonatal rat CDCs was compared to in old and young rats including evaluation of blood, echocardiographic, haemodynamic and treadmill stress tests. For in vitro studies, human heart progenitors from older donors, or cardiomyocytes from aged rats were exposed to human CDCs or cardiosphere derived cell (CDC) derived exosomes (CDC-XO) from pediatric donors. CDCs and CDC-XOs were capable of effectuating youthful patterns of gene expression in the hearts of old, along with a variant of physiological and function benefits, including elongation of telomere length. Together, these results indicate capacity of CDCs and CDC-XO to ward off the effects of aging through rejuvenation.